Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (RAR beta) agonists

• Main Authors: BROWN JANE THERESA, DE CASTRO VASCONCELOS GONCALVES MARIA BEATRIZ, BORTHWICK ALAN DAVID, MILLS MARK TREVOR, CORCORAN JONATHAN PATRICK THOMAS, KALINDJIAN SARKIS BARRET
• Format: Patent
• Language: Chinese; English
• Published: 26.09.2017
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain bicycloheteroaryl-heteroaryl-benzoic acid compounds of the following formula (for convenience, collectively referred to herein as "BHBA compounds"), which, inter alia, are (selective) retinoic acid receptor beta (RAR beta) (e.g., RAR beta 2) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR beta (e.g., RAR beta 2), to cause or promote neurite development, neurite outgrowth, and/or neurite regeneration, and in the treatment of diseases and conditions that are mediated by RAR beta (e.g., RAR beta 2), that are ameliorated by the activation of RAR beta (e.g., RAR beta 2), etc., including, e.g., neurological injuries such as spinal cord injuries. 本发明通常涉及治疗性化合物领域，并且更具体地涉及下式的某些双环杂芳基-杂芳基-苯甲酸化合物(为方便起见，本文中统称为"BHBA化合物")，它们尤其是(选择性的)视黄酸受体β(RARβ)(例如，RARβ2)